Literature DB >> 24664191

Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome.

Angela Bauer1, Sebastian Loos, Carola Wehrmann, Dirk Horstmann, Frank Donnerstag, Johanna Lemke, Georg Hillebrand, Ulrike Löbel, Lars Pape, Dieter Haffner, Carola Bindt, Thurid Ahlenstiel, Anette Melk, Anja Lehnhardt, Markus J Kemper, Jun Oh, Hans Hartmann.   

Abstract

BACKGROUND: The aim of this study was to analyze the neurological involvement and outcome in pediatric patients with hemolytic uremic syndrome (HUS) during the 2011 epidemic caused by Escherichia coli O104:H4.
METHODS: Clinical data and data from magnetic resonance imaging (MRI) scans and electroencephalography (EEG) during the acute phase of the disease and during follow-up at 3 and 6 months were analyzed in 50 patients. Twenty-five of these patients underwent neuropsychological testing (WISC IV) during follow-up.
RESULTS: Neurological involvement (stupor or coma, seizures, visual disturbances, paresis, myocloni) was initially observed in 14/50 (28%) patients. One patient died. EEG abnormalities were more frequent in patients with neurological involvement than in those without (12/14 vs. 13/25, respectively). Cranial MRI scans were analyzed in nine patients with neurological involvement, of whom five showed abnormal findings. At the 3- and 6-month follow-ups, EEG abnormalities were found in 14/40 (35%) and 7/36 (19%) patients, respectively, whereas 28/42 (67%) and 17/39 (44%) patients, respectively, complained about on-going reduced performance. Neuropsychological testing showed a slightly lower global intelligence quotient in patients with neurological involvement versus those without (113.4 ± 2.8 vs. 119.4 ± 1.8, respectively).
CONCLUSIONS: Neurological involvement was frequent in our cohort. Accordingly, the incidence of pathological EEG findings was high, even in patients without clinical signs of neurological involvement. Nevertheless, major neurological sequelae were rare, and neuropsychological outcome was favorable after 6 months.

Entities:  

Mesh:

Year:  2014        PMID: 24664191     DOI: 10.1007/s00467-014-2803-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  Neurological complications of hemolytic-uremic syndrome.

Authors:  J S Hahn; P L Havens; J J Higgins; P P O'Rourke; J A Estroff; R Strand
Journal:  J Child Neurol       Date:  1989-04       Impact factor: 1.987

Review 2.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

3.  Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement.

Authors:  Frank Donnerstag; Xiaoqi Ding; Lars Pape; Eva Bültmann; Thomas Lücke; Jan Zajaczek; Ludwig Hoy; Anibh Martin Das; Heinrich Lanfermann; Jochen Ehrich; Hans Hartmann
Journal:  Eur Radiol       Date:  2011-10-08       Impact factor: 5.315

4.  Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Authors:  Sylvie Nathanson; Thérésa Kwon; Monique Elmaleh; Marina Charbit; Emma Allain Launay; Jérôme Harambat; Muriel Brun; Bruno Ranchin; Flavio Bandin; Sylvie Cloarec; Guylhene Bourdat-Michel; Christine Piètrement; Gérard Champion; Tim Ulinski; Georges Deschênes
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

5.  An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.

Authors:  Sebastian Loos; Thurid Ahlenstiel; Brigitta Kranz; Hagen Staude; Lars Pape; Christoph Härtel; Udo Vester; Laura Buchtala; Kerstin Benz; Bernd Hoppe; Ortraud Beringer; Martin Krause; Dominik Müller; Martin Pohl; Johanna Lemke; Georg Hillebrand; Martin Kreuzer; Jens König; Marianne Wigger; Martin Konrad; Dieter Haffner; Jun Oh; Markus J Kemper
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

6.  Sequelae of haemolytic uraemic syndrome.

Authors:  A Schlieper; P C Rowe; E Orrbine; M Zoubek; W Clark; N Wolfish; P N McLaine
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

7.  CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis.

Authors:  J F Bale; C Brasher; R L Siegler
Journal:  Am J Dis Child       Date:  1980-09

8.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

Review 9.  Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome.

Authors:  E G Gallo; C A Gianantonio
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

Review 10.  The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak.

Authors:  Helge Karch; Erick Denamur; Ulrich Dobrindt; B Brett Finlay; Regine Hengge; Ludgers Johannes; Eliora Z Ron; Tone Tønjum; Philippe J Sansonetti; Miguel Vicente
Journal:  EMBO Mol Med       Date:  2012-08-24       Impact factor: 12.137

View more
  13 in total

Review 1.  Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.

Authors:  Werner Keenswijk; Ann Raes; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2017-12-29       Impact factor: 3.183

2.  Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome.

Authors:  Kathrin Buder; Beatrice Latal; Samuel Nef; Thomas J Neuhaus; Guido F Laube; Giuseppina Spartà
Journal:  Pediatr Nephrol       Date:  2014-09-19       Impact factor: 3.714

3.  A diagnosis of haemolytic-uraemic syndrome blurred by alcohol abuse.

Authors:  Martin Killian; Noémie Bruel Tronchon; Nicolas Maillard; Bernard Tardy
Journal:  BMJ Case Rep       Date:  2014-12-24

4.  Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).

Authors:  Myda Khalid; Sharon Andreoli
Journal:  Pediatr Nephrol       Date:  2018-11-01       Impact factor: 3.714

5.  Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome.

Authors:  Clare C Brown; Xiomara Garcia; Rupal T Bhakta; Emily Sanders; Parthak Prodhan
Journal:  Pediatrics       Date:  2021-02-12       Impact factor: 7.124

6.  Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.

Authors:  Lars Pape; Hans Hartmann; Franz Christoph Bange; Sebastian Suerbaum; Eva Bueltmann; Thurid Ahlenstiel-Grunow
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 7.  Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.

Authors:  Heidi Ko; Hossein Maymani; Cristhiam Rojas-Hernandez
Journal:  J Med Case Rep       Date:  2016-06-15

8.  Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography.

Authors:  Ulrike Löbel; Nils Daniel Forkert; Peter Schmitt; Thorsten Dohrmann; Maria Schroeder; Tim Magnus; Stefan Kluge; Christina Weiler-Normann; Xiaoming Bi; Jens Fiehler; Jan Sedlacik
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

Review 9.  Public Health Research Resulting from One of the World's Largest Outbreaks Caused by Entero-Hemorrhagic Escherichia coli in Germany 2011: A Review.

Authors:  Elena Köckerling; Laura Karrasch; Aparna Schweitzer; Oliver Razum; Gérard Krause
Journal:  Front Public Health       Date:  2017-12-11

10.  Alternating hemiparesis in the context of hemolytic uremic syndrome and COVID-19 positivity.

Authors:  Hugh D Simpson; Erica Johnson; Jeffrey Britton; Sherri Braksick
Journal:  Epilepsy Behav Rep       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.